Superworth

Orchestra BioMed price to sales ratio OBIO

Market value divided by revenue over the last twelve months, since 2024.

Today, Nov 2, 2026
10.7×
3-year median
61.1×
Against its 3-year history
20th
percentile: 0 is its lowest day, 100 its highest
3-year range
6.7× to 132×
Peer median
1.7×

Orchestra BioMed's price to sales ratio is 10.7× as of Nov 2, 2026.

That is below its 3-year median of 61.1×, lower than on 80% of days in the last 3 years.

Over that time it ranged from 6.7× in Jul 2026 to 132× in Jun 2024.

The median for 10 medical instruments and supplies stocks of a similar size is 1.7×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far10.7×6.7×96.2×
202586.6×32.4×107×
202463.2×56.9×132×

Against its peers

Companies in Medical - Instruments & Supplies nearest Orchestra BioMed's size, closest first, today.

CompanyPrice to sales ratio
OBIOOrchestra BioMed10.7×
EMBCEmbecta0.3×
INFUInfuSystem1.9×
TCMDTactile Systems Technology1.5×
UTMDUtah Medical Products6.2×
PDEXPro DEX2.3×
MOVMovado1.0×
IRMDIradimed11.4×
IARTIntegra Lifesciences0.6×
BVSBioventus1.9×
KEQUKewaunee Scientific0.3×
Peer median1.7×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Orchestra BioMed

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.